Zeta Beats Again, But Growth Quality Gap Widens Valuation Risk

What happened

Zeta's Q1 2026 revenue surged 50% to $396M and adjusted EBITDA rose 42%, propelled by Athena AI adoption and enterprise wallet share gains. However, the headline growth masks that underlying expansion is only 22-23% when excluding political candidate and acquired Marigold revenue, per management's own bridge. The market's beat-and-raise enthusiasm has pushed the stock to $18.6, a level the DeepValue report considers demanding given the gap between reported and organic growth. Meanwhile, insider gifting patterns and heavy stock-based compensation raise concerns about per-share dilution exceeding management's 3-4% target. The critical test is whether Q2 2026 can sustain the cadence and if RPO continues to expand, or if the growth quality gap will lead to multiple compression.

Implication

Patience is warranted; wait for two quarters of evidence that ex-acquisition growth holds above 25% and RPO keeps rising, which would support the bull case of $28.

Thesis delta

The Q1 beat and guidance raise reinforce the bull narrative but do not close the growth quality gap. The underlying 22-23% organic growth is consistent with the base case, but the stock now trades above the base case implied value of $20. The thesis shifts from 'wait for cleaner visibility' to 'visibility is slightly clearer but still incomplete; the elevated valuation demands either a pullback or stronger proof of organic acceleration.' The DeepValue report's WAIT rating remains appropriate, but the conviction may increase slightly if Q2 confirms the trend.